Atlas Trials

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

Clinical trial NCT04285723 · COMPLETED

Trial details

NCT number
NCT04285723
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
PIK3CA-Related Overgrowth Spectrum (PROS)
Start date
2020-06-09
Primary completion
2021-04-16
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.